Aeterna discontinues vaccine development; Idera rebrands as Aceragen
As biotechs start to detail 2023 plans — M&A, new emphases in drug R&D and more with investors — others are starting to trim back or using …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
